Paper37698552
Recent Advances in Anti-Atherosclerosis and Potential Therapeutic Targets for Nanomaterial-Derived Drug Formulations.
Xiao Z and 11 others. Adv Sci (Weinh), 2023. Cited by 27 papers, by iCite.
Cite this record
ConductScience Library. Recent Advances in Anti-Atherosclerosis and Potential Therapeutic Targets for Nanomaterial-Derived Drug Formulations. Papers, record 37698552. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/37698552
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Recent Advances in Anti-Atherosclerosis and Potential Therapeutic Targets for Nanomaterial-Derived Drug Formulations.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Nanostructures | Major topic |
| Nanoparticles | Major topic |
| Atherosclerosis | Major topic |
| Humans | |
| Drug Delivery Systems | |
| Drug Compounding |
Source PubMed
Grants3
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 20ZR1420000 | Natural Science Foundation of Shanghai | PubMed | ||
| 21S21902100 | Science and Technology Support Project in Biomedical Field of Science and Technology Innovation Action Plan of Shanghai Science and Technology Commission | PubMed | ||
| 2021-HSD-8-6-001 | Baoshan Zhaohui New Drug R & D and Transformation Functional Platform | PubMed |
Source PubMed
References164
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31218557 | Folate Conjugated Double Liposomes Bearing Prednisolone and Methotrexate for Targeting Rheumatoid Arthritis. | Pharm Res | 2019 | https://conductscience.org/library/papers/31218557 | PubMed |
| 2 | 19435455 | Current advances in research and clinical applications of PLGA-based nanotechnology. | Expert Rev Mol Diagn | 2009 | https://conductscience.org/library/papers/19435455 | PubMed |
| 3 | 27562774 | Diverse macrophages polarization in tumor microenvironment. | Arch Pharm Res | 2016 | https://conductscience.org/library/papers/27562774 | PubMed |
| 4 | 30354259 | Impact of miRNA in Atherosclerosis. | Arterioscler Thromb Vasc Biol | 2018 | https://conductscience.org/library/papers/30354259 | PubMed |
| 5 | 35982578 | Use of acidic nanoparticles to rescue macrophage lysosomal dysfunction in atherosclerosis. | Autophagy | 2023 | https://conductscience.org/library/papers/35982578 | PubMed |
| 6 | 28011379 | Heart targeted nanoliposomal/nanoparticles drug delivery: An updated review. | Biomed Pharmacother | 2017 | https://conductscience.org/library/papers/28011379 | PubMed |
| 7 | 17848087 | Depletion of folate-receptor-positive macrophages leads to alleviation of symptoms and prolonged survival in two murine models of systemic lupus erythematosus. | Mol Pharm | 2007 | https://conductscience.org/library/papers/17848087 | PubMed |
| 8 | 24941020 | Fumagillin prodrug nanotherapy suppresses macrophage inflammatory response via endothelial nitric oxide. | ACS Nano | 2014 | https://conductscience.org/library/papers/24941020 | PubMed |
| 9 | 26706498 | Endothelial dysfunction and vascular disease - a 30th anniversary update. | Acta Physiol (Oxf) | 2017 | https://conductscience.org/library/papers/26706498 | PubMed |
| 10 | 29751694 | Solubility of Cyclodextrins and Drug/Cyclodextrin Complexes. | Molecules | 2018 | https://conductscience.org/library/papers/29751694 | PubMed |
| 11 | 29937375 | Chlamydia pneumoniae Hijacks a Host Autoregulatory IL-1β Loop to Drive Foam Cell Formation and Accelerate Atherosclerosis. | Cell Metab | 2018 | https://conductscience.org/library/papers/29937375 | PubMed |
| 12 | 29851288 | Pleiotropic effects of the hemostatic system. | J Thromb Haemost | 2018 | https://conductscience.org/library/papers/29851288 | PubMed |
| 13 | 14707059 | Innate immune discrimination of apoptotic cells: repression of proinflammatory macrophage transcription is coupled directly to specific recognition. | J Immunol | 2004 | https://conductscience.org/library/papers/14707059 | PubMed |
| 14 | 26757788 | Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study. | Eur Heart J | 2016 | https://conductscience.org/library/papers/26757788 | PubMed |
| 15 | 31822793 | Efferocytosis in health and disease. | Nat Rev Immunol | 2020 | https://conductscience.org/library/papers/31822793 | PubMed |
| 16 | 19754375 | Oxidative stress, endothelial dysfunction and atherosclerosis. | Curr Pharm Des | 2009 | https://conductscience.org/library/papers/19754375 | PubMed |
| 17 | 15668126 | The mannose receptor: linking homeostasis and immunity through sugar recognition. | Trends Immunol | 2005 | https://conductscience.org/library/papers/15668126 | PubMed |
| 18 | 35999079 | ROS responsive nanoparticles loaded with lipid-specific AIEgen for atherosclerosis-targeted diagnosis and bifunctional therapy. | Biomaterials | 2022 | https://conductscience.org/library/papers/35999079 | PubMed |
| 19 | 24385509 | ATP-binding cassette transporters, atherosclerosis, and inflammation. | Circ Res | 2014 | https://conductscience.org/library/papers/24385509 | PubMed |
| 20 | 3475709 | Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. | Proc Natl Acad Sci U S A | 1987 | https://conductscience.org/library/papers/3475709 | PubMed |
Cited by14
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 27 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42939558 | Irisin in Cardiovascular Health and Disease: A Review of Its Function as a Biomarker and Therapeutic Target in Atherosclerosis and Related Conditions. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/42939558 | PubMed |
| 42608966 | Prodrug Strategies in Atherosclerosis: Targeted Delivery and Therapeutic Advances. | Cardiovasc Ther | 2026 | https://conductscience.org/library/papers/42608966 | PubMed |
| 42569353 | Nanozyme-based therapeutic strategies for traumatic brain injury. | Int J Pharm X | 2026 | https://conductscience.org/library/papers/42569353 | PubMed |
| 42093999 | Studies of chitosan-Prussian blue nanozyme in auditory protection: from cellular mechanisms to in vivo validation. | Front Immunol | 2026 | https://conductscience.org/library/papers/42093999 | PubMed |
| 41494239 | Nanotechnology for atherosclerotic plaque stabilisation: bridging innovation and clinical practice. | EBioMedicine | 2026 | https://conductscience.org/library/papers/41494239 | PubMed |
| 41137064 | Nano-therapeutics targeting the macrophage-based microenvironment in the treatment of atherosclerosis. | J Transl Med | 2025 | https://conductscience.org/library/papers/41137064 | PubMed |
| 40985304 | A Hypoxia-Responsive Single-Atom Sonozyme for Targeted Sonocatalytic Therapy in Alleviating Atherosclerotic Plaque. | Adv Sci (Weinh) | 2025 | https://conductscience.org/library/papers/40985304 | PubMed |
| 40896801 | Macrophage-Targeted Nanomedicine for the Treatment of Atherosclerosis. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/40896801 | PubMed |
| 40546800 | Combined Oxaliplatin with 5-Fluorouracil for Effective Chemotherapy Against Gastric Cancer in Animal Model. | Int J Nanomedicine | 2025 | https://conductscience.org/library/papers/40546800 | PubMed |
| 40521521 | The Role of ROS in Atherosclerosis and ROS-Based Nanotherapeutics for Atherosclerosis: Atherosclerotic Lesion Targeting, ROS Scavenging, and ROS-Responsive Activity. | ACS Omega | 2025 | https://conductscience.org/library/papers/40521521 | PubMed |
| 39917726 | Biomimetic nanoparticles co-deliver hirudin and lumbrukinase to ameliorate thrombus and inflammation for atherosclerosis therapy. | Asian J Pharm Sci | 2025 | https://conductscience.org/library/papers/39917726 | PubMed |
| 39116306 | Minimally Invasive Injectable Gel for Local Immunotherapy of Liver and Gastric Cancer. | Adv Sci (Weinh) | 2024 | https://conductscience.org/library/papers/39116306 | PubMed |
| 39036340 | Biomedical applications of stimuli-responsive nanomaterials. | MedComm (2020) | 2024 | https://conductscience.org/library/papers/39036340 | PubMed |
| 37698552 | Recent Advances in Anti-Atherosclerosis and Potential Therapeutic Targets for Nanomaterial-Derived Drug Formulations. | Adv Sci (Weinh) | 2023 | https://conductscience.org/library/papers/37698552 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| IL6 | 3569 | PubTator's text mining | https://conductscience.org/library/genes/3569 | NCBI Gene |
| PCSK9 | 255738 | PubTator's text mining | https://conductscience.org/library/genes/255738 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/37698552
GET https://conductscience.org/api/papers/v1/37698552/references?page=2